Skip to main content Skip to main content
Go to homepage

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Description:

For complete information, please view the study on clinicaltrials.gov.

This study is being done in collaboration with Cincinnati Children's Hospital.

Study Status:
Closed
Full IRB Study Title:
ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
IRB Study ID:
1042403-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.